So I was browsing around the internet today, and I noticed that a new drug called vedolizumab is entering phase III clinical trials. This drug isn't a new anti-TNF, which I suppose is a good thing, as we already have at least three of those on the market, and we need to break some new ground. Instead, it's more of an improved version of Tysabri. Supposedly, since vedolizumab targets the alpha4beta7 integrin rather than just the alpha4 integrin like Tysabri, it can "modulate inflammation specifically in the GI tract without systemic immunosuppression", thus making it able to "confer efficacy in IBD with an improved safety profile and risk-to-benefit ratio".
Science babble here. Hopefully it'll be as good of a drug as the article makes out, and work for people that anti-TNFa's were ineffective for, minus risk factors like Tysabri's PML. And so long as it survives its phase III trials it could be on the market soon, I'd think. Keep your eyes peeled.
Science babble here. Hopefully it'll be as good of a drug as the article makes out, and work for people that anti-TNFa's were ineffective for, minus risk factors like Tysabri's PML. And so long as it survives its phase III trials it could be on the market soon, I'd think. Keep your eyes peeled.